- Home
- CLYM vs CLLS Comparison
CLYM vs CLLS Comparison
Compare CLYM & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLYM
- CLLS
- Stock Information
- Founded
- CLYM 2018
- CLLS 1999
- Country
- CLYM United States
- CLLS France
- Employees
- CLYM N/A
- CLLS N/A
- Industry
- CLYM
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- CLYM
- CLLS Health Care
- Exchange
- CLYM NYSE
- CLLS Nasdaq
- Market Cap
- CLYM 201.7M
- CLLS 240.2M
- IPO Year
- CLYM 2021
- CLLS 2007
- Fundamental
- Price
- CLYM $3.05
- CLLS $1.87
- Analyst Decision
- CLYM
- CLLS Buy
- Analyst Count
- CLYM 0
- CLLS 3
- Target Price
- CLYM N/A
- CLLS $7.00
- AVG Volume (30 Days)
- CLYM 342.1K
- CLLS 91.2K
- Earning Date
- CLYM 11-12-2024
- CLLS 11-04-2024
- Dividend Yield
- CLYM N/A
- CLLS N/A
- EPS Growth
- CLYM N/A
- CLLS N/A
- EPS
- CLYM N/A
- CLLS N/A
- Revenue
- CLYM N/A
- CLLS $36,042,000.00
- Revenue This Year
- CLYM N/A
- CLLS $271.02
- Revenue Next Year
- CLYM N/A
- CLLS $33.48
- P/E Ratio
- CLYM N/A
- CLLS N/A
- Revenue Growth
- CLYM N/A
- CLLS 46.96
- 52 Week Low
- CLYM $2.35
- CLLS $1.70
- 52 Week High
- CLYM $11.55
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- CLYM N/A
- CLLS 47.31
- Support Level
- CLYM N/A
- CLLS $1.82
- Resistance Level
- CLYM N/A
- CLLS $1.98
- Average True Range (ATR)
- CLYM 0.00
- CLLS 0.10
- MACD
- CLYM 0.00
- CLLS 0.01
- Stochastic Oscillator
- CLYM 0.00
- CLLS 56.67
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.